Skip to main content

Judd Wendell Moul, MD

James H. Semans, M.D. Distinguished Professor of Urologic Surgery, in the School of Medicine
Professor of Surgery
Professor in Anesthesiology
Office: 1573 White Zone, Duke South, Durham, NC 27710
Campus Mail: DUMC Box 3707 Med Ctr, Durham, NC 27710

Dr Judd Moul joined the Duke faculty in mid 2004 after a career in the US Army Medical Corps mainly at Walter Reed Army Medical Center.  He is a retired colonel and a noted researcher and clinician in the area of prostate cancer and is a urologic oncologist. He served as the division chief of Duke Division of Urology from 2004 to 2011 and was named the James H Semans MD Professor of surgery in 2009 becoming Duke's first named endowed chair for urology.  He was awarded the Gold Cystoscope Award from the American Urologic Association as well as Castle Connelly Physician of the year for Clinical Medicine in 2009.  He has performed more than 1300 radical prostatectomies since joining the Duke faculty and is committed to outcomes research on this series and in other areas of prostate cancer.  He served as the Editor for Prostate Cancer and Prostatic Dissease, a Nature Medicine journal, for more than a decade and is a popular speaker and lecturer having been visiting professor and keynote speaker throughout the US and the World.  He is very committed to training residents and mentoring students and trainees. 

Education and Training

  • Fellowship, Urologic Oncology, Duke University, 1988 - 1989
  • Residency, Urology, Walter Reed Army Medical Center, 1983 - 1987
  • Residency, Surgery, Walter Reed Army Medical Center, 1982 - 1983
  • M.D., Thomas Jefferson University, 1982
  • B.S., Pennsylvania State University, 1979

Publications

Catalona, William J., Anthony V. D’Amico, William F. Fitzgibbons, Omofolasade Kosoko-Lasaki, Stephen W. Leslie, Henry T. Lynch, Judd W. Moul, Marc S. Rendell, and Patrick C. Walsh. “What the U.S. Preventive Services Task Force missed in its prostate cancer screening recommendation.” Ann Intern Med 157, no. 2 (July 17, 2012): 137–38. https://doi.org/10.7326/0003-4819-157-2-201207170-00463.

Full Text

Yu, Evan Y., Kurt Miller, Joel Nelson, Martin Gleave, Karim Fizazi, Judd W. Moul, Faith E. Nathan, and Celestia S. Higano. “Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer.” J Urol 188, no. 1 (July 2012): 103–9. https://doi.org/10.1016/j.juro.2012.03.008.

Full Text

Moul, J. W. “Minimally invasive open retropubic prostatectomy: in experienced hands--still the gold standard.” Oncology (Williston Park, N.Y.) 26, no. 7 (July 1, 2012).

Scholars@Duke

Moul, Judd W. “Minimally invasive open retropubic prostatectomy: in experienced hands--still the gold standard.” Oncology (Williston Park) 26, no. 7 (July 2012): 610–15.

Scholars@Duke

Kimura, Masaki, Zahid N. Rabbani, Andrew R. Zodda, Hui Yan, Isabel L. Jackson, Thomas J. Polascik, Craig F. Donatucci, Judd W. Moul, Zeljko Vujaskovic, and Bridget F. Koontz. “Role of oxidative stress in a rat model of radiation-induced erectile dysfunction.” J Sex Med 9, no. 6 (June 2012): 1535–49. https://doi.org/10.1111/j.1743-6109.2012.02716.x.

Full Text

Bassett, Mitchell, Michael Abern, Lionel Lloyds Banez, Michael Ferrandino, Cary N. Robertson, Brant Allen Inman, Thomas Polascik, Stephen J. Freedland, Philip John Walther, and Judd W. Moul. “African American race to predict for earlier failure of active surveillance: Results from the Duke Prostate Center.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.

Scholars@Duke

Moul, Judd W., Hans Lilja, Oliver John Semmes, Robert Vessella, Jonathan E. McDermed, Mark J. Sarno, and Robert E. Klem. “= 7 disease.” In Journal of Clinical Oncology, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.

Scholars@Duke

Moul, J. W. “In the pipeline: Galeterone lowers PSA in CRPC study: Commentary.” Oncology Report, May 1, 2012.

Scholars@Duke

Moul, J. W. “Men avoid therapy for sexual side effects of prostatectomy: Commentary.” Oncology Report, May 1, 2012.

Scholars@Duke

Moul, J. W. “Radiotherapy comparison favors IMRT for prostate cancer: Commentary.” Oncology Report, May 1, 2012.

Scholars@Duke

Pages